Literature DB >> 9207018

A new peptide vector for efficient delivery of oligonucleotides into mammalian cells.

M C Morris1, P Vidal, L Chaloin, F Heitz, G Divita.   

Abstract

The development of antisense and gene therapy has focused mainly on improving methods for oligonucleotide and gene delivery into cells. In the present work, we describe a potent new strategy for oligonucleotide delivery based on the use of a short peptide vector, termed MPG (27 residues), which contains a hydrophobic domain derived from the fusion sequence of HIV gp41 and a hydrophilic domain derived from the nuclear localization sequence of SV40 T-antigen. The formation of peptide vector/oligonucleotide complexes was investigated by measuring changes in intrinsic tryptophan fluorescence of peptide and of mansyl-labelled oligonucleotides. MPG exhibits relatively high affinity for both single- and double-stranded DNA in a nanomolar range. Based on both intrinsic and extrinsic fluorescence titrations, it appears that the main binding between MPG and oligonucleotides occurs through electrostatic interactions, which involve the basic-residues of the peptide vector. Further peptide/peptide interactions also occur, leading to a higher MPG/oligonucleotide ratio (in the region of 20/1), which suggests that oligonucleotides are most likely coated with several molecules of MPG. Premixed complexes of peptide vector with single or double stranded oligonucleotides are delivered into cultured mammalian cells in less than 1 h with relatively high efficiency (90%). This new strategy of oligonucleotide delivery into cultured cells based on a peptide vector offers several advantages compared to other commonly used approaches of delivery including efficiency, stability and absence of cytotoxicity. The interaction with MPG strongly increases both the stability of the oligonucleotide to nuclease and crossing of the plasma membrane. The mechanism of cell delivery of oligonucleotides by MPG does not follow the endosomal pathway, which explains the rapid and efficient delivery of oligonucleotides in the nucleus. As such, we propose this peptide vector as a powerful tool for potential development in gene and antisense therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207018      PMCID: PMC146800          DOI: 10.1093/nar/25.14.2730

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  30 in total

1.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.

Authors:  P L Felgner; T R Gadek; M Holm; R Roman; H W Chan; M Wenz; J P Northrop; G M Ringold; M Danielsen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 2.  Strategies for targeted gene therapy.

Authors:  J D Harris; N R Lemoine
Journal:  Trends Genet       Date:  1996-10       Impact factor: 11.639

3.  Solid-phase synthesis and cellular localization of a C- and/or N-terminal labelled peptide.

Authors:  P Vidal; L Chaloin; J Méry; N Lamb; N Lautredou; R Bennes; F Heitz
Journal:  J Pept Sci       Date:  1996 Mar-Apr       Impact factor: 1.905

Review 4.  Antisense oligonucleotides: towards clinical trials.

Authors:  S Agrawal
Journal:  Trends Biotechnol       Date:  1996-10       Impact factor: 19.536

5.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

6.  Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus.

Authors:  W R Gallaher
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

7.  Sequence requirements for nuclear location of simian virus 40 large-T antigen.

Authors:  D Kalderon; W D Richardson; A F Markham; A E Smith
Journal:  Nature       Date:  1984 Sep 6-11       Impact factor: 49.962

8.  A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA.

Authors:  J G Lewis; K Y Lin; A Kothavale; W M Flanagan; M D Matteucci; R B DePrince; R A Mook; R W Hendren; R W Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

9.  Expression and activity of serum response factor is required for expression of the muscle-determining factor MyoD in both dividing and differentiating mouse C2C12 myoblasts.

Authors:  C Gauthier-Rouviere; M Vandromme; D Tuil; N Lautredou; M Morris; M Soulez; A Kahn; A Fernandez; N Lamb
Journal:  Mol Biol Cell       Date:  1996-05       Impact factor: 4.138

10.  Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues.

Authors:  M D Delahunty; I Rhee; E O Freed; J S Bonifacino
Journal:  Virology       Date:  1996-04-01       Impact factor: 3.616

View more
  105 in total

1.  Delivery of oligonucleotides into mammalian cells by anionic peptides: comparison between monomeric and dimeric peptides.

Authors:  I Freulon; A C Roche; M Monsigny; R Mayer
Journal:  Biochem J       Date:  2001-03-15       Impact factor: 3.857

2.  Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells.

Authors:  Federica Simeoni; May C Morris; Frederic Heitz; Gilles Divita
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

Review 3.  Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors.

Authors:  Guillaume Drin; Christophe Rousselle; Jean-Michel Scherrmann; Anthony R Rees; Jamal Temsamani
Journal:  AAPS PharmSci       Date:  2002

Review 4.  Improvement of DNA transfection with cationic liposomes.

Authors:  A Rocha; S Ruiz; J M Coll
Journal:  J Physiol Biochem       Date:  2002-03       Impact factor: 4.158

Review 5.  Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

Authors:  Xiao-Xiang Zhang; Henry S Eden; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-10-26       Impact factor: 9.776

6.  Optimized synthesis of phosphorothioate oligodeoxyribonucleotides substituted with a 5'-protected thiol function and a 3'-amino group.

Authors:  Y Aubert; S Bourgerie; L Meunier; R Mayer; A C Roche; M Monsigny; N T Thuong; U Asseline
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

7.  Modified poly(lactic-co-glycolic acid) nanoparticles for enhanced cellular uptake and gene editing in the lung.

Authors:  Rachel J Fields; Elias Quijano; Nicole Ali McNeer; Christina Caputo; Raman Bahal; Kavi Anandalingam; Marie E Egan; Peter M Glazer; W Mark Saltzman
Journal:  Adv Healthc Mater       Date:  2014-08-25       Impact factor: 9.933

8.  The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells.

Authors:  Marc S Weinberg; Louisa M Villeneuve; Ali Ehsani; Mohammed Amarzguioui; Lars Aagaard; Zhao-Xia Chen; Arthur D Riggs; John J Rossi; Kevin V Morris
Journal:  RNA       Date:  2005-12-22       Impact factor: 4.942

Review 9.  The taming of the cell penetrating domain of the HIV Tat: myths and realities.

Authors:  Ashok Chauhan; Akshay Tikoo; Arvinder K Kapur; Mahavir Singh
Journal:  J Control Release       Date:  2006-11-17       Impact factor: 9.776

10.  Rational design of a biomimetic cell penetrating peptide library.

Authors:  Emmanouil D Karagiannis; Aleksandra M Urbanska; Gaurav Sahay; Jeisa M Pelet; Siddharth Jhunjhunwala; Robert Langer; Daniel G Anderson
Journal:  ACS Nano       Date:  2013-09-30       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.